CA2445612A1 - Methods and compositions for treating mammalian nerve tissue injuries - Google Patents

Methods and compositions for treating mammalian nerve tissue injuries Download PDF

Info

Publication number
CA2445612A1
CA2445612A1 CA002445612A CA2445612A CA2445612A1 CA 2445612 A1 CA2445612 A1 CA 2445612A1 CA 002445612 A CA002445612 A CA 002445612A CA 2445612 A CA2445612 A CA 2445612A CA 2445612 A1 CA2445612 A1 CA 2445612A1
Authority
CA
Canada
Prior art keywords
glycol
composition
injury
fusion agent
nerve tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002445612A
Other languages
French (fr)
Other versions
CA2445612C (en
Inventor
Riyi Shi
Richard B. Borgens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Riyi Shi
Richard B. Borgens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Riyi Shi, Richard B. Borgens filed Critical Purdue Research Foundation
Priority to CA2740056A priority Critical patent/CA2740056A1/en
Publication of CA2445612A1 publication Critical patent/CA2445612A1/en
Application granted granted Critical
Publication of CA2445612C publication Critical patent/CA2445612C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

To achieve, an in vivo repair of injured mammalian nerve tissue, an effectiv e amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injur y. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusi on agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tiss ue injury.

Claims (21)

1. Pharmaceutical composition for use in treating an injury to nerve tissue of a mammalian patient, the composition comprising an effective amount of a biomembrane fusion agent formulated for delivery via the patient's vascular system to the site of the injured nerve tissue; and optionally a pharmaceutical carrier.
2. Use of a biomembrane fusion agent for the preparation of a pharmaceutical composition for treatment of an injury to nerve tissue of a mammalian patient.
3. Method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a biomembrane fusion agent and optionally a pharmaceutical carrier to the patient so that biomembrane fusion agent is delivered via the patient's vascular system to the site of the injured nerve tissue.
4. The composition, use or method of any of the preceding claims wherein said biomembrane fusion agent comprises at least one hydrophilic polymer.
5. The composition, use or method of claim 4 wherein said hydrophilic polymer comprises at least one polyalkylene glycol.
6. The composition, use or method of claim 5 wherein said polyalkylene glycol is taken from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers thereof.
7. The composition, use or method of claim 5 wherein said polyalkylene glycol comprises polyethylene glycol.
8. The composition, use or method of claim 4 wherein said hydrophilic polymer comprises a dextran.
9. The composition, use or method of claim 8 wherein said hydrophilic polymer has a molecular weight of about 400 daltons to about 3500 daltons.
10. The composition, use or method of any of claims 1 to 3 wherein the biomembrane fusion agent comprises an amphipathic polymer.
11. The composition, use or method of claim 10 wherein said amphipathic polymer comprises a block copolymer.
12. The composition, use or method of claim 11 wherein said block copolymer is taken from the group consisting of polyalkylene glycol block copolymers, mixtures of polyalkylene glycol block copolymers, and mixtures of polyalkylene glycols and polyalkylene glycol block copolymers.
13. The composition, use or method of claim 11 wherein said block copolymer comprises at least one compound taken from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers thereof.
14. The composition, use or method of any of claims 10 to 13 wherein said amphipathic polymer is taken from the group consisting of polyethylene glycol/polypropylene glycol block copolymers, and mixtures of polyethylene glycol, polypropylene glycol, and polyethylene glycol/polypropylene glycol block copolymers.
15. The composition, use or method of claim 10 wherein said amphipathic polymer is taken from the group consisting of poloxamers and poloxamines.
16. The composition, use or method of any of the preceding claims wherein the injured nerve tissue is spinal cord tissue.
17. The composition, use or method of any of claims 1 to 15 wherein the injured nerve tissue is peripheral nerve tissue.
18. The composition, use or method any of the preceding claims wherein the injury is a mechanical injury, a biochemical injury and/or an ischemic injury.
19. The composition, use or method of claim 18 wherein the ischemic injury is a stroke and/or a head injury.
20. The pharmaceutical composition of any of claims 1 and 4 to 19 wherein said effective amount of said biomembrane fusion agent is effective for injecting said biomembrane fusion agent intraveneously, intramuscularly, subcutaneously, or intraperitoneally into the patient, or into or near the nerve sheath at the site of injury.
21. The method of any of claims 3 to 19 wherein administration of an effective amount of said biomembrane fusion agent is effected using a technique selected from the group consisting of intravascular, intramuscular, subcutaneous and intraperitoneal injection, or by injecting said biomembrane fusion agent into or near the nerve sheath at the site of injury.
CA2445612A 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries Expired - Fee Related CA2445612C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2740056A CA2740056A1 (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28620001P 2001-04-24 2001-04-24
US60/286,200 2001-04-24
PCT/US2002/013375 WO2002092107A1 (en) 2001-04-24 2002-04-24 Method and compositions for treating mammalian nerve tissue injuries

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2740056A Division CA2740056A1 (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Publications (2)

Publication Number Publication Date
CA2445612A1 true CA2445612A1 (en) 2002-11-21
CA2445612C CA2445612C (en) 2011-10-25

Family

ID=23097525

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2445612A Expired - Fee Related CA2445612C (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries
CA2740056A Abandoned CA2740056A1 (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2740056A Abandoned CA2740056A1 (en) 2001-04-24 2002-04-24 Methods and compositions for treating mammalian nerve tissue injuries

Country Status (9)

Country Link
US (4) US7837987B2 (en)
EP (1) EP1389121B1 (en)
JP (2) JP2004527573A (en)
AT (1) ATE546146T1 (en)
AU (2) AU2002314758B2 (en)
CA (2) CA2445612C (en)
ES (1) ES2382899T3 (en)
NZ (2) NZ529526A (en)
WO (1) WO2002092107A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582680B1 (en) 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CA2445612C (en) * 2001-04-24 2011-10-25 Purdue Research Foundation Methods and compositions for treating mammalian nerve tissue injuries
US7147647B2 (en) 2002-04-26 2006-12-12 Medtronic, Inc. Sintered titanium tube for the management of spinal cord injury
JP4571776B2 (en) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 Lubricating oil composition
EP1618179B1 (en) 2003-04-18 2014-05-07 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
CN101043899B (en) * 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 Refolding transforming growth factor beta family proteins
MX2007002029A (en) * 2004-08-19 2007-03-28 Biogen Idec Inc Neublastin variants.
WO2006044738A2 (en) * 2004-10-18 2006-04-27 Maroon Biotech Corporation Methods and compositions for treatment of free radical injury
DE602005014672D1 (en) * 2004-12-21 2009-07-09 Lubrizol Ltd Compositions
US20070048731A1 (en) * 2005-05-20 2007-03-01 Neurosilicon High throughput use-dependent assay based on stimulation of cells on a silicon surface
JP5259392B2 (en) 2005-05-31 2013-08-07 ウォーソー・オーソペディック・インコーポレーテッド Compositions and methods for treating pain
US20070017530A1 (en) * 2005-06-10 2007-01-25 Syed Naweed I Detecting electrical activity and assessing agents for the ability to influence electrical activity
US20060287660A1 (en) * 2005-06-15 2006-12-21 Syed Naweed I Electrically Stimulating Nerve Regeneration
US20060292549A1 (en) * 2005-06-15 2006-12-28 Neurosilicon Psychotropic drug screening device based on long-term photoconductive stimulation of neurons
JP4907908B2 (en) * 2005-06-29 2012-04-04 ルネサスエレクトロニクス株式会社 Driving circuit and display device
WO2007009235A1 (en) * 2005-07-15 2007-01-25 Neurosilicon (1145990 Alberta Ltd.) Method and apparatus for guiding growth of neurons
US20070213822A1 (en) * 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Treatment of the vertebral column
US20070213718A1 (en) * 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Treatment of the vertebral column
US20070227547A1 (en) * 2006-02-14 2007-10-04 Sdgi Holdings, Inc. Treatment of the vertebral column
US20070213717A1 (en) * 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Biological fusion in the vertebral column
TWI501774B (en) * 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
ES2450065T3 (en) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Compositions and methods for the administration of GDNF ligand family proteins
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US8945623B2 (en) * 2006-05-03 2015-02-03 Warsaw Orthopedic, Inc. Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
US9675696B2 (en) 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
TWI445544B (en) * 2007-05-01 2014-07-21 Biogen Idec Inc Compositions and methods for increasing vascularization
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20090263507A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
JP5795961B2 (en) * 2008-10-21 2015-10-14 ザ ジェネラル ホスピタル コーポレイション Cell transplantation
US9078808B2 (en) * 2009-03-26 2015-07-14 Warsaw Orthopedic, Inc. Device to deliver magnesium in PEG formulation
US8858924B2 (en) * 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
US8852566B2 (en) 2009-03-26 2014-10-07 Warsaw Orthopedic, Inc. Compositions and methods for preferential distribution of active agents to injury sites
CN102438657A (en) 2009-03-26 2012-05-02 沃萨乌整形外科公司 Methods of identifying potential components for targeted drug delivery compositions
US9244060B2 (en) * 2009-03-26 2016-01-26 Warsaw Orthopedic, Inc. Site localization and methods for monitoring treatment of disturbed blood vessels
WO2010118178A2 (en) 2009-04-07 2010-10-14 Garfield Robert E Uterine electrical stimulation system and method
US20110230785A1 (en) * 2010-03-16 2011-09-22 ProNerve, LLC Somatosensory Evoked Potential (SSEP) Automated Alert System
WO2012019103A2 (en) 2010-08-06 2012-02-09 The General Hospital Corporation D/B/A System and apparatus for cell treatment
CA3063888C (en) 2010-10-27 2020-12-22 Dignity Health Uterine electrical stimulation system and method
US9872983B2 (en) 2010-10-27 2018-01-23 Dignity Health Uterine electrical stimulation system and method
WO2012161823A1 (en) * 2011-02-25 2012-11-29 The General Hospital Corporation D/B/A Massachusetts General Hospital Nerve coaptation apparatus
US20150127017A1 (en) * 2012-05-18 2015-05-07 Robert E. Garfield Electrical stimulation of the cervix
WO2014124142A2 (en) * 2013-02-07 2014-08-14 The Cleveland Clinic Foundation Methods of treating spinal cord injury
CN106663137B (en) 2014-04-28 2020-07-10 耶达研究及发展有限公司 Method and apparatus for predicting reaction to food
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
KR102653455B1 (en) 2017-07-26 2024-04-02 뉴랩티브 테라퓨틱스, 인크. Device and method for creating a fluid containment field for administering a therapeutic agent to a nerve
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
EP4034134A4 (en) * 2019-09-27 2023-10-18 Virginia Commonwealth University Compositions and methods for restoring or increasing tissue perfusion
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
US20230058178A1 (en) * 2020-01-21 2023-02-23 The Penn State Research Foundation Methods and materials for treating nerve injury and/or promoting wound healing
JP2023532915A (en) * 2020-07-09 2023-08-01 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント Methods for protecting cells from injury
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369769A (en) 1980-06-13 1983-01-25 Edwards Charles C Spinal fixation device and method
US4599354A (en) 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US4919140A (en) 1988-10-14 1990-04-24 Purdue Research Foundation Method and apparatus for regenerating nerves
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
NL9000634A (en) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting WATER-BASED SUSPENSION INJECTION PREPARATION, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THIS PREPARATION FOR PAIN RELIEF.
EP0522134A1 (en) * 1991-01-11 1993-01-13 COBE Laboratories, Inc. Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
ES2140408T3 (en) 1991-03-19 2000-03-01 Cytrx Corp POLYOXYPROPYLENE / POLYOXYETHYLENE COPOLYMERS WITH IMPROVED BIOLOGICAL ACTIVITY.
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5324322A (en) * 1992-04-20 1994-06-28 Case Western Reserve University Thin film implantable electrode and method of manufacture
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
DK0582164T3 (en) 1992-07-31 1999-08-23 Bristol Myers Squibb Co Adenosine reuptake inhibitory derivatives of diphenyloxazoles, thiazoles and imidazoles
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
DE69614050T2 (en) * 1995-02-14 2002-03-21 Toray Industries FLAT PRESSURE PLATE
JPH09315972A (en) 1996-03-22 1997-12-09 Chugai Pharmaceut Co Ltd Therapeutic drug for damaged spinal code
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
EP1024812B1 (en) 1997-03-19 2007-01-24 Sky High, LLC Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US7582680B1 (en) * 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6432434B1 (en) * 1999-04-22 2002-08-13 The United States Of America As Represented By The Secretary Of The Army Treatment of and/or prophylaxis against brain and spinal cord injury
CA2445612C (en) * 2001-04-24 2011-10-25 Purdue Research Foundation Methods and compositions for treating mammalian nerve tissue injuries
EP1583544A4 (en) 2002-12-30 2008-10-22 Purdue Research Foundation Method of treatment for central nervous system injury

Also Published As

Publication number Publication date
US8460646B2 (en) 2013-06-11
JP2004527573A (en) 2004-09-09
EP1389121A1 (en) 2004-02-18
CA2740056A1 (en) 2002-11-21
AU2006200866A1 (en) 2006-03-23
US20140100289A1 (en) 2014-04-10
US9687502B2 (en) 2017-06-27
ES2382899T3 (en) 2012-06-14
US20100016444A1 (en) 2010-01-21
NZ529526A (en) 2006-06-30
AU2002314758B2 (en) 2006-06-01
US20050069520A1 (en) 2005-03-31
US9101655B2 (en) 2015-08-11
JP2009112835A (en) 2009-05-28
US20030118545A1 (en) 2003-06-26
WO2002092107A1 (en) 2002-11-21
CA2445612C (en) 2011-10-25
NZ543953A (en) 2007-04-27
US7837987B2 (en) 2010-11-23
AU2006200866B2 (en) 2007-11-08
EP1389121B1 (en) 2012-02-22
EP1389121A4 (en) 2006-11-02
ATE546146T1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
CA2445612A1 (en) Methods and compositions for treating mammalian nerve tissue injuries
JP2004527573A5 (en)
JP5242415B2 (en) Pharmacological composition with high stability
CA2657911C (en) Pharmaceutical compositions for sustained release delivery of peptides
JP3220331B2 (en) Absorbable liquid copolymers for parenteral administration
US20080152668A1 (en) Thymosin Alpha 1 Peptide/Polymer Conjugates
US20090258079A1 (en) Biocompatible Block Copolymer, Use Thereof and Manufacturing Method Thereof
JP2004525712A (en) Method and apparatus for delivery of high molecular weight substances
WO1999053943A3 (en) Therapeutic angiogenic factors and methods for their use
EP3478300B1 (en) Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2012150265A1 (en) Fiber comprising a biodegradable polymer
AU2002353964A1 (en) Thymosin alpha 1 peptide/polymer conjugates
WO2002072019A2 (en) Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
CA2506893A1 (en) Methods of protecting against radiation damage using alpha thymosin
Patel et al. A review: Parenteral depot drug delivery system
CN111511385B (en) Pharmaceutical composition with selected duration of release
EP3624815A1 (en) Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
EP2396026A2 (en) Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
Semmler et al. 67. Silk-silk Conduits Filled with Native Spider Silk Fibers Successfully Promoted Nerve Regeneration in a 10 Mm Sciatic Nerve Defect in Rats
KR20220151995A (en) Liraglutide-loaded Microneedle formulation
CN116831975A (en) Microneedle patch for inducing immune tolerance to treat rheumatoid arthritis
GB2346329A (en) Injection device
AU6177499A (en) Pharmaceutical composition containing stimulators of interferon-gamma

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160425